JPMorgan Chase Issues Notes Linked to Alnylam Pharmaceuticals Common Stock

JPMorgan Chase & Co., through its direct and wholly-owned finance subsidiary JPMorgan Chase Financial Company LLC, is issuing a new type of financial instrument linked to Alnylam Pharmaceuticals' common stock. The notes have a principal amount of $1,000 and will pay a contingent interest payment of $13.625 (16.35% per annum) if the closing price of one share of Alnylam's stock on any interest review date is greater than or equal to 50% of the strike value ($123.755). The notes are scheduled to mature on September 13, 2029.

If the notes have not been automatically called and the final value is less than the trigger value (50% of the strike value), investors will lose more than 50% of their principal amount at maturity. However, if the closing price of one share of Alnylam's stock on any autocall review date is greater than or equal to the strike value ($247.51), the notes will be automatically called for a cash payment.

The pricing date for these notes is September 11, 2026, and the original issue date (settlement date) is on or about September 16, 2026. The interest review dates are October 12, 2026, November 10, 2026, December 10, 2026, January 11, 2027, February 10, 2027, March 10, 2027, April 12, 2027, May 10, 2027, June 10, 2027, July 12, 2027, August 10, 2027, September 10, 2027, October 11, 2027, November 10, 2027, December 10, 2027, January 10, 2028, February 10, 2028, March 10, 2028, April 10, 2028, May 10, 2028, June 12, 2028, July 10, 2028, August 10, 2028, September 11, 2028, October 10, 2028, November 10, 2028, December 11, 2028, January 10, 2029, February 12, 2029, March 12, 2029, April 10, 2029, May 10, 2029, June 11, 2029, July 10, 2029, August 10, 2029, and September 10, 2029.